News | Radiopharmaceuticals and Tracers | April 05, 2017

GE Healthcare Signs Agreement With HealthTrust to Supply Radiopharmaceuticals

Member hospitals of Nashville-based organization will receive extended access to products that support the diagnosis and care of oncological, cardiological and neurological diseases

GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals

April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered in Nashville, Tenn., to provide both low-energy (SPECT) and high-energy (PET) radiopharmaceuticals to HealthTrust members across the United States. The agreement commenced on March 1, 2017.

GE Healthcare’s core imaging business manufactures pharmaceuticals that are used in the fields of radiology and nuclear medicine to assist physicians in diagnosing a range of diseases, including cancer and cardiovascular and neurological diseases. Through this agreement, HealthTrust member facilities will have access to Life Sciences Core Imaging single-photon emission computed tomography (SPECT) proprietary products, such as Myoview, Ceretec and Indium-Oxine, as well as non-GE Healthcare products, such as MDP, Indium In-111, Thallium chloride and Sodium Iodide 1-123 capsules.

HealthTrust serves approximately 1,600 acute care facilities and members in more than 26,000 other locations, including ambulatory surgery centers, physician practices, long-term care and alternate care sites.

For more information: www.gehealthcare.com

Related Content

CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging| September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Videos | Nuclear Imaging| August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging| August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging| June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Videos | Nuclear Imaging| April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging| January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging| January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging| January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging| December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
Overlay Init